Lenalidomida Teva (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4 E3 ubiquitin ligase complex. This binding changes the complex’s target proteins, leading to degradation of transcription factors that support cancer cell survival, while also enhancing immune‑mediated tumor cell killing and inhibiting new blood‑vessel formation.

The specific dose and schedule of Lenalidomida Teva are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Only a qualified healthcare professional should set the dosing regimen.

Lenalidomide is classified as potentially teratogenic, and its safety in pregnancy has not been established. Women of childbearing potential must use effective contraception, and the drug should be avoided during pregnancy and breastfeeding unless the benefits clearly outweigh the risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism from proteasome inhibitors or monoclonal antibodies. It is often used in combination regimens and provides oral administration, which can be more convenient than injectable alternatives, while delivering comparable efficacy in many clinical settings.

Lenalidomida Teva should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

The medication is taken orally, usually with a glass of water. It may be prescribed with or without food depending on the physician’s instructions. Patients should follow the dosing schedule provided by their healthcare provider and not alter the regimen without medical advice.

Serious risks include venous thromboembolism, severe skin reactions such as Stevens‑Johnson syndrome, secondary primary malignancies, and profound cytopenias that can lead to infection or bleeding. Patients should be monitored closely for these events and report any concerning symptoms promptly.

Lenalidomida Teva is contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation, in pregnant women, and in individuals with severe uncontrolled infections or uncontrolled thrombotic disorders unless appropriate prophylaxis is in place.